Assessment of cataract formation after intravitreal use of triamcinolone acetonid and triamcinolone/bevacizumab combination: 1 year results

Session Details

Session Title: Presented Poster Session: IOL Opacification

Venue: Poster Village: Pod 1

First Author: : N.Palarie MOLDOVA

Co Author(s): :    T. Pasenco   L. Vudu                    

Abstract Details

Purpose:

The purpose of this randomized retrospective study is to assess cataract formation after intravitreal use of triamcinolon acetonid (IVTA) and triamcinolon/bevacizumab (IVTA/IVB) combination.

Setting:

International Clinic, Orhei, Moldova State University of Medicine and Pharmacy "Nicolae Testemitanu", Chisinau, Moldova

Methods:

There were 47 eyes of 35 patients with diabetic macular edema included in the study. Best corrected visual acuity was 0,3 ± 0,1 LogMAR. Patients were matched by age, gender and randomized into 2 groups: patients in the 1st group (n=23 eyes) received 3 monthly consecutive IVTA 2 mg injections, patients in the 2nd group received 3 monthly consecutive IVTA/IVB (2mg+1,25mg) injections.

Results:

The follow-up period varied from 12 months to 1,2 year. Patients were followed at week 2 after any injection, months 1, 3, 6 and 12 following last injection. Posterior subcapsular cataract formation was noticed in 7 eyes (30%) in the 1st group and in 2 eyes in the 2nd group (8%) at the end of the follow up period. Transient intraocular pressure (IOP) rise was observed in 4 eyes in the 1st group and in 3 eyes in the 2nd group. IOP came back to normal at the end of the follow up period.

Conclusions:

IVTA/IVB (2mg+1,25mg) combined injections do not cause posterior subcapsular cataract formation as often as IVTA 2 mg alone in 1 year follow up period. Both types of injections do not cause permanent IOP rise in a long term follow up.

Financial Disclosure:

None